A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics

1.

Takei H, Araki A, Watanabe H et al (1996) Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis. J Leukoc Biol 59:229–240. https://doi.org/10.1002/jlb.59.2.229CrossRefPubMed

2.

Brinkmann V, Zychlinsky A (2012) Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 198:773–783PubMedPubMedCentralCrossRef

3.

Brinkmann V, Zychlinsky A (2007) Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 5:577–582. https://doi.org/10.1038/nrmicro1710CrossRefPubMed

4.

Urban C, Zychlinsky A (2007) Netting bacteria in sepsis. Nat Med 13:403–404PubMedCrossRef

5.

Scapini P, Cassatella MA (2014) Social networking of human neutrophils within the immune system. Blood 124:710–719PubMedCrossRef

6.

Amulic B, Cazalet C, Hayes GL et al (2012) Neutrophil function: from mechanisms to disease. Annu Rev Immunol 30:459–489. https://doi.org/10.1146/annurev-immunol-020711-074942CrossRefPubMed

7.

Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531PubMedCrossRef

8.

Brinkmann V, Reichard U, Goosmann C et al (2004) Neutrophil extracellular traps kill bacteria. Science 303(80):1532–1535. https://doi.org/10.1126/science.1092385CrossRefPubMed

9.

Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A (2010) Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191:677–691. https://doi.org/10.1083/jcb.201006052CrossRefPubMedPubMedCentral

10.

Reeves EP, Lu H, Jacobs HL et al (2002) Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416:291–297. https://doi.org/10.1038/416291aCrossRefPubMed

11.

Smith CK, Vivekanandan-Giri A, Tang C et al (2014) Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheum 66:2532–2544. https://doi.org/10.1002/art.38703CrossRef

12.

Parker H, Winterbourn CC (2013) Reactive oxidants and myeloperoxidase and their involvement in neutrophil extracellular traps. Front Immunol 3:424. https://doi.org/10.3389/fimmu.2012.00424CrossRefPubMedPubMedCentral

13.

Hawez A, Al-Haidari A, Madhi R et al (2019) MiR-155 regulates PAD4-dependent formation of neutrophil extracellular traps. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.02462

14.

Lewis HD, Liddle J, Coote JE et al (2015) Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol 11:189–191. https://doi.org/10.1038/nchembio.1735CrossRefPubMedPubMedCentral

15.

Wang Y, Li M, Stadler S et al (2009) Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 184:205–213. https://doi.org/10.1083/jcb.200806072CrossRefPubMedPubMedCentral

16.

Martinod K, Demers M, Fuchs TA et al (2013) Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. Proc Natl Acad Sci U S A 110:8674–8679. https://doi.org/10.1073/pnas.1301059110CrossRefPubMedPubMedCentral

17.

Branzk N, Lubojemska A, Hardison SE et al (2014) Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 15:1017–1025. https://doi.org/10.1038/ni.2987CrossRefPubMedPubMedCentral

18.

Segal AW (2005) How neutrophils kill microbes. Annu Rev Immunol 23:197–223. https://doi.org/10.1146/annurev.immunol.23.021704.115653CrossRefPubMedPubMedCentral

19.

Petretto A, Bruschi M, Pratesi F et al (2019) Neutrophil extracellular traps (NET) induced by different stimuli: a comparative proteomic analysis. PLoS One 14:e0218946. https://doi.org/10.1371/journal.pone.0218946CrossRefPubMedPubMedCentral

20.

Bruschi M, Bonanni A, Petretto A et al (2020) Neutrophil extracellular traps profiles in patients with incident systemic lupus erythematosus and lupus nephritis. J Rheumatol 47:377–386. https://doi.org/10.3899/jrheum.181232CrossRefPubMed

21.

Park J, Wysocki RW, Amoozgar Z et al (2016) Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med 8. https://doi.org/10.1126/scitranslmed.aag1711

22.

Liu D, Yang P, Gao M et al (2019) NLRP3 activation induced by neutrophil extracellular traps sustains inflammatory response in the diabetic wound. Clin Sci 133:565–582. https://doi.org/10.1042/CS20180600CrossRef

23.

Hirota T, Levy JH, Iba T (2020) The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation. https://doi.org/10.1111/micc.12617

24.

Clark SR, Ma AC, Tavener SA et al (2007) Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13:463–469. https://doi.org/10.1038/nm1565CrossRefPubMed

25.

Vogel S, Bodenstein R, Chen Q et al (2015) Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 125:4638–4654. https://doi.org/10.1172/JCI81660CrossRefPubMedPubMedCentral

26.

Etulain J, Martinod K, Wong SL et al (2015) P-selectin promotes neutrophil extracellular trap formation in mice. Blood 126:242–246. https://doi.org/10.1182/blood-2015-01-624023CrossRefPubMedPubMedCentral

27.

Schauer C, Janko C, Munoz LE et al (2014) Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 20:511–517. https://doi.org/10.1038/nm.3547CrossRefPubMed

28.

Neumann A, Berends ETM, Nerlich A et al (2014) The antimicrobial peptide LL-37 facilitates the formation of neutrophil extracellular traps. Biochem J 464:3–11. https://doi.org/10.1042/BJ20140778CrossRefPubMed

29.

Burgener SS, Schroder K (2019) Neutrophil extracellular traps in host defense. https://doi.org/10.1101/cshperspect.a037028

30.

Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L et al (2017) Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol 8:81PubMedPubMedCentralCrossRef

31.

Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus - a comprehensive review. Clin Rev Allergy Immunol 45:331–379PubMedPubMedCentralCrossRef

32.

Saitoh T, Komano J, Saitoh Y et al (2012) Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe 12:109–116. https://doi.org/10.1016/j.chom.2012.05.015CrossRefPubMed

33.

Narasaraju T, Yang E, Samy RP et al (2011) Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol 179:199–210. https://doi.org/10.1016/j.ajpath.2011.03.013CrossRefPubMedPubMedCentral

34.

Muraro SP, De Souza GF, Gallo SW et al (2018) Respiratory syncytial virus induces the classical ROS-dependent NETosis through PAD-4 and necroptosis pathways activation. Sci Rep 8:1–12. https://doi.org/10.1038/s41598-018-32576-yCrossRef

35.

Gwyer Findlay E, Currie SM, Davidson DJ (2013) Cationic host defence peptides: potential as antiviral therapeutics. BioDrugs 27:479–493PubMedPubMedCentralCrossRef

36.

Hoeksema M, Tripathi S, White M et al (2015) Arginine-rich histones have strong antiviral activity for influenza a viruses. Innate Immun 21:736–745. https://doi.org/10.1177/1753425915593794CrossRefPubMed

37.

McCormick A, Heesemann L, Wagener J et al (2010) NETs formed by human neutrophils inhibit growth of the pathogenic mold Aspergillus fumigatus. Microbes Infect 12:928–936. https://doi.org/10.1016/j.micinf.2010.06.009CrossRefPubMed

38.

Amulic B, Knackstedt SL, Abu Abed U et al (2017) Cell-cycle proteins control production of neutrophil extracellular traps. Dev Cell 43:449–462.e5. https://doi.org/10.1016/j.devcel.2017.10.013CrossRefPubMed

39.

Bruns S, Kniemeyer O, Hasenberg M et al (2010) Production of extracellular traps against aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin roda. PLoS Pathog 6:1–18. https://doi.org/10.1371/journal.ppat.1000873CrossRef

40.

Carroll GM, Burns GL, Petit JA et al (2020) Does postoperative inflammation or sepsis generate neutrophil extracellular traps that influence colorectal cancer progression? A systematic review. Surg Open Sci. https://doi.org/10.1016/j.sopen.2019.12.005

41.

Baker VS, Imade GE, Molta NB et al (2008) Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age. Malar J:7. https://doi.org/10.1186/1475-2875-7-41

42.

Abdallah DSA, Lin C, Ball CJ et al (2012) Toxoplasma gondii triggers release of human and mouse neutrophil extracellular traps. Infect Immun 80:768–777. https://doi.org/10.1128/IAI.05730-11CrossRef

43.

Guimarães-Costa AB, Nascimento MTC, Froment GS et al (2009) Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A 106:6748–6753. https://doi.org/10.1073/pnas.0900226106CrossRefPubMedPubMedCentral

44.

Díaz-Godínez C, Carrero JC (2019) The state of art of neutrophil extracellular traps in protozoan and helminthic infections. Biosci Rep. https://doi.org/10.1042/BSR20180916

45.

Cools-Lartigue J, Spicer J, Najmeh S, Ferri L (2014) Neutrophil extracellular traps in cancer progression. Cell Mol Life Sci 71:4179–4194PubMedPubMedCentralCrossRef

46.

Richardson JJR, Hendrickse C, Gao-Smith F, Thickett DR (2017) Neutrophil extracellular trap production in patients with colorectal cancer in vitro. https://doi.org/10.1155/2017/4915062

47.

Snoderly HT, Boone BA, Bennewitz MF (2019) Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment. Breast Cancer Res 21:1–13CrossRef

48.

Alfaro C, Teijeira A, Oñate C et al (2016) Tumor-produced Interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res 22:3924–3936. https://doi.org/10.1158/1078-0432.CCR-15-2463CrossRefPubMed

49.

Zhu L, Liu L, Zhang Y et al (2018) High level of neutrophil extracellular traps correlates with poor prognosis of severe influenza a infection. J Infect Dis 217:428–437. https://doi.org/10.1093/infdis/jix475CrossRefPubMed

50.

Li RHL, Johnson LR, Kohen C, Tablin F (2018) A novel approach to identifying and quantifying neutrophil extracellular trap formation in septic dogs using immunofluorescence microscopy. BMC Vet Res 14:1–7. https://doi.org/10.1186/s12917-018-1523-zCrossRef

51.

Thålin C, Hisada Y, Lundström S et al (2019) Neutrophil extracellular traps. Arterioscler Thromb Vasc Biol 39:1724–1738. https://doi.org/10.1161/ATVBAHA.119.312463CrossRefPubMedPubMedCentral

52.

Li RHL, Tablin F (2018) A comparative review of neutrophil extracellular traps in sepsis. Front Vet Sci 5:291PubMedPubMedCentralCrossRef

53.

Ekaney ML, Otto GP, Sossdorf M et al (2014) Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation. Crit Care 18:543. https://doi.org/10.1186/s13054-014-0543-8CrossRefPubMedPubMedCentral

54.

Akgul C, Moulding DA, Edwards SW (2001) Molecular control of neutrophil apoptosis. FEBS Lett 487:318–322PubMedCrossRef

55.

Keshari RS, Jyoti A, Dubey M et al (2012) Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One:7. https://doi.org/10.1371/journal.pone.0048111

56.

Xu J, Zhang X, Pelayo R et al (2009) Extracellular histones are major mediators of death in sepsis. Nat Med 15:1318–1321. https://doi.org/10.1038/nm.2053CrossRefPubMedPubMedCentral

57.

Abrams ST, Zhang N, Manson J et al (2013) Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med 187:160–169. https://doi.org/10.1164/rccm.201206-1037OCCrossRefPubMedPubMedCentral

58.

Gupta S, Kaplan MJ (2016) The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol 12:402–413PubMedPubMedCentralCrossRef

59.

Glennon-Alty L, Hackett AP, Chapman EA, Wright HL (2018) Neutrophils and redox stress in the pathogenesis of autoimmune disease. Free Radic Biol Med 125:25–35. https://doi.org/10.1016/j.freeradbiomed.2018.03.049CrossRefPubMed

60.

Hoffmann JHO, Enk AH (2016) Neutrophil extracellular traps in dermatology: caught in the NET. J Dermatol Sci 84:3–10PubMedCrossRef

61.

Engler D, Chezuba HP, Masuku P (2017) Psoriasis. SA Pharm J 84:38–42

62.

Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873PubMedCrossRef

63.

Boehncke WH, Schön MP (2015) Psoriasis. Lancet 386:983–994PubMedCrossRef

64.

Pinegin B, Vorobjeva N, Pinegin V (2015) Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 14:633–640PubMedCrossRef

65.

Witko-Sarsat V, Pederzoli-Ribeil M, Hirsh E et al (2011) Regulating neutrophil apoptosis: new players enter the game. Trends Immunol 32:117–124PubMedCrossRef

66.

Dörner T, Giesecke C, Lipsky PE (2011) Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 13. https://doi.org/10.1186/ar3433

67.

Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. In: The Lancet. Lancet Publishing Group, p 1878–1888. https://doi.org/10.1016/S0140-6736(14)60128-8

68.

Pan L, Lu MP, Wang JH et al (2020) Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 16:19–30PubMedCrossRef

69.

Odqvist L, Jevnikar Z, Riise R et al (2019) Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann Rheum Dis 78:1363–1370. https://doi.org/10.1136/annrheumdis-2019-215434CrossRefPubMed

70.

Chen W, Wang Q, Ke Y et al (2018) Review article neutrophil function in an inflammatory milieu of rheumatoid arthritis. https://doi.org/10.1155/2018/8549329

71.

Carmona-Rivera C, Carlucci PM, Moore E et al (2017) Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. Sci Immunol 2. https://doi.org/10.1126/sciimmunol.aag3358

72.

Hidalgo AI, Carretta MD, Alarcón P et al (2019) Pro-inflammatory mediators and neutrophils are increased in synovial fluid from heifers with acute ruminal acidosis. BMC Vet Res 15:1–10. https://doi.org/10.1186/s12917-019-1974-xCrossRef

73.

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5:178ra40. https://doi.org/10.1126/scitranslmed.3005580CrossRefPubMedPubMedCentral

74.

Apel F, Zychlinsky A, Kenny EF (2018) The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol 14:467–475PubMedCrossRef

75.

Wigerblad G, Kaplan MJ (2020) NETs spread ever wider in rheumatic diseases. Nat Rev Rheumatol 16:73–74PubMedCrossRef

76.

Herold KC, Vignali DAA, Cooke A, Bluestone JA (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13:243–256PubMedPubMedCentralCrossRef

77.

Berezin A (2019) Neutrophil extracellular traps: the core player in vascular complications of diabetes mellitus. Diabetes Metab Syndr Clin Res Rev 13:3017–3023CrossRef

78.

Jennette JC, Falk RJ (1997) Small-vessel vasculitis. N Engl J Med 337:1512–1523. https://doi.org/10.1056/NEJM199711203372106CrossRefPubMed

79.

Hunder GG, Arend WP, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis: introduction. Arthritis Rheum 33:1065–1067. https://doi.org/10.1002/art.1780330802CrossRefPubMed

80.

Goeser MR, Laniosz V, Wetter DA (2014) A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol 15:299–306. https://doi.org/10.1007/s40257-014-0076-6CrossRefPubMed

81.

Nakazawa D, Tomaru U, Yamamoto C et al (2012) Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis. Front Immunol 3. https://doi.org/10.3389/fimmu.2012.00333

82.

Nakazawa D, Shida H, Tomaru U et al (2014) Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol 25:990–997. https://doi.org/10.1681/ASN.2013060606CrossRefPubMedPubMedCentral

83.

Mitroulis I, Kambas K, Chrysanthopoulou A et al (2011) Neutrophil extracellular trap formation is associated with IL-1β and autophagy-related signaling in gout. PLoS One. https://doi.org/10.1371/journal.pone.0029318

84.

Lee KH, Kronbichler A, Park DDY et al (2017) Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev 16:1160–1173. https://doi.org/10.1016/j.autrev.2017.09.012

85.

Desai J, Steiger S, Anders HJ (2017) Molecular pathophysiology of gout. Trends Mol Med

86.

Chambers TJ, Morson BC (1979) The granuloma in Crohn’s disease. Gut 20:269–274. https://doi.org/10.1136/gut.20.4.269CrossRefPubMedPubMedCentral

87.

Hedin CRH, Vavricka SR, Stagg AJ et al (2019) Gene and Mirna regulatory networks during different stages of Crohn’s disease. J Crohn's Colitis 13:541–554. https://doi.org/10.1093/ECCO-JCCCrossRef

88.

Rogers BHG, Clark LM, Kirsner JB (1971) The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. J Chronic Dis 24:743–773. https://doi.org/10.1016/0021-9681(71)90087-7CrossRefPubMed

89.

Parkes G, Clare S, Goulding D et al (2006) Neutrophil activation and neutrophil extracellular trap formation in inflammatory bowel disease. Gastroenterology 130:A235

90.

Gottlieb Y, Elhasid R, Berger-Achituv S et al (2018) Neutrophil extracellular traps in pediatric inflammatory bowel disease. Pathol Int. https://doi.org/10.1111/pin.12715

91.

Dinallo V, Marafini I, Di Fusco D et al (2019) Neutrophil extracellulartraps sustain inflammatory signals in ulcerative colitis. J Crohn's Colitis. https://doi.org/10.1093/ecco-jcc/jjy215

92.

Wärnberg J, Marcos A (2008) Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr Opin Lipidol 19:11–15PubMedCrossRef

93.

Castro AM, Macedo-de la Concha LE, Pantoja-Meléndez CA (2017) Low-grade inflammation and its relation to obesity and chronic degenerative diseases. Rev Médica del Hosp Gen México 80:101–105. https://doi.org/10.1016/j.hgmx.2016.06.011CrossRef

94.

Wong SL, Demers M, Martinod K et al (2015) Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med. https://doi.org/10.1038/nm.3887

95.

Frühbeck G (2004) The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents 2:197–208PubMedCrossRef

96.

Maurizi G, Della Guardia L, Maurizi A, Poloni A (2018) Adipocytes properties and crosstalk with immune system in obesity-related inflammation. J Cell Physiol 233:88–97. https://doi.org/10.1002/jcp.25855CrossRefPubMed

97.

Bonaventura A, Vecchié A, Abbate A, Montecucco F (2020) Neutrophil extracellular traps and cardiovascular diseases: an update. Cells 9:231. https://doi.org/10.3390/cells9010231CrossRefPubMedCentral

98.

D’Abbondanza M, Martorelli EE, Ricci MA et al (2019) Increased plasmatic NETs by-products in patients in severe obesity. Sci Rep 9:1–10. https://doi.org/10.1038/s41598-019-51220-xCrossRef

99.

Narayana Moorthy A, Narasaraju T, Rai P et al (2013) In vivo and in vitro studies on the roles of neutrophil extracellular traps during secondary pneumococcal pneumonia after primary pulmonary influenza infection. Front Immunol 4:56. https://doi.org/10.3389/fimmu.2013.00056CrossRefPubMedPubMedCentral

100.

Moorthy AN, Tan KB, Wang S et al (2016) Effect of high-fat diet on the formation of pulmonary neutrophil extracellular traps during influenza pneumonia in BALB/c mice. Front Immunol 7:289. https://doi.org/10.3389/fimmu.2016.00289CrossRefPubMedPubMedCentral

101.

Tarantino E, Amadio P, Squellerio I et al (2016) Role of thromboxane-dependent platelet activation in venous thrombosis: aspirin effects in mouse model. Pharmacol Res 107:415–425. https://doi.org/10.1016/j.phrs.2016.04.001CrossRefPubMed

102.

Caudrillier A, Kessenbrock K, Gilliss BM et al (2012) Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122:2661–2671. https://doi.org/10.1172/JCI61303CrossRefPubMedPubMedCentral

103.

Ortiz-Muñoz G, Mallavia B, Bins A et al (2014) Aspirin-triggered 15-epi-lipoxin a4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Blood. https://doi.org/10.1182/blood-2014-03-562876

104.

Offermanns S (2006) Activation of platelet function through G protein-coupled receptors. Circ Res 99:1293–1304PubMedCrossRef

105.

Chen J, Shetty S, Zhang P et al (2014) Aspirin-triggered resolvin D1 down-regulates inflammatory responses and protects against endotoxin-induced acute kidney injury. Toxicol Appl Pharmacol. https://doi.org/10.1016/j.taap.2014.03.017

106.

Tilgner J, Von Trotha KT, Gombert A et al (2016) Aspirin, but NotTirofiban displays protective effects in endotoxin induced lung injury. PLoS One. https://doi.org/10.1371/journal.pone.0161218

107.

Sayah DM, Mallavia B, Liu F et al (2015) Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 191:455–463. https://doi.org/10.1164/rccm.201406-1086OCCrossRefPubMedPubMedCentral

108.

Lapponi MJ, Carestia A, Landoni VI et al (2013) Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345:430–437. https://doi.org/10.1124/jpet.112.202879CrossRefPubMed

109.

Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47:119–125. https://doi.org/10.1016/S0162-3109(00)00192-2

110.

Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transp Secur. https://doi.org/10.1155/2012/230386

111.

Palmeiro BS (2013) Cyclosporine in veterinary dermatology. Vet Clin North Am Small Anim Pract (43), 153–171. https://doi.org/10.1016/j.cvsm.2012.09.007

112.

Liberman AC, Druker J, Refojo D, Arzt E (2008) Molecular mechanisms of action of some immunosuppressive drugs. Medicina 68:455–464

113.

Gupta AK, Giaglis S, Hasler P, Hahn S (2014) Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A. PLoS One:9. https://doi.org/10.1371/journal.pone.0097088

114.

Fric J, Zelante T, Wong AYW et al (2012) NFAT control of innate immunity. Blood 120:1380–1389. https://doi.org/10.1182/blood-2012-02-404475

115.

Jha V, Chugh KS (2002) Posttransplant infections in the tropical countries. Artif Organs. https://doi.org/10.1046/j.1525-1594.2002.07069.x

116.

Witalison EE, Cui X, Causey CP et al (2015) Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer. Oncotarget. https://doi.org/10.18632/oncotarget.5937

117.

Knight JS, Subramanian V, O’dell AA et alPeptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. https://doi.org/10.1136/annrheumdis-2014-205365

118.

Fadini GP, Menegazzo L, Rigato M et al (2016) NETosis delays diabetic wound healing in mice and humans. Diabetes. https://doi.org/10.2337/db15-0863

119.

Nakashima K, Arai S, Suzuki A et al (2013) PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun. https://doi.org/10.1038/ncomms2862

120.

Stadler SC, Vincent CT, Fedorov VD et al (2013) Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelialto-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.1308362110

121.

Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V (2015) Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science (80). https://doi.org/10.1126/science.aaa8064

122.

Ricciotti E, Fitzgerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. https://doi.org/10.1161/ATVBAHA.110.207449

123.

Gad SE (2014) Prostaglandins. In: Encyclopedia of toxicology, third edn

124.

Shishikura K, Horiuchi T, Sakata N et al (2016) Prostaglandin E2 inhibits neutrophil extracellular trap formation through production of cyclic AMP. Br J Pharmacol 173:319–331. https://doi.org/10.1111/bph.13373CrossRefPubMed

125.

Domingo-Gonzalez R, Martínez-Colón GJ, Smith AJ et al (2016) Inhibition of neutrophil extracellular trap formation after stem cell transplant by prostaglandin E2. Am J Respir Crit Care Med 193:186–197. https://doi.org/10.1164/rccm.201501-0161OCCrossRefPubMedPubMedCentral

126.

Fabricius D, Neubauer M, Mandel B et al (2010) Prostaglandin E 2 inhibits IFN-α secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol. https://doi.org/10.4049/jimmunol.0902028

127.

Zipfel PF, Heinen S, Józsi M, Skerka C (2006) Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 43: 97–106. https://doi.org/10.1016/j.molimm.2005.06.015

128.

Java A, Atkinson J, Salmon J (2013) Defective complement inhibitory function predisposes to renal disease. Annu Rev Med. https://doi.org/10.1146/annurev-med-072211-110606

129.

de Bont CM, Boelens WC, Pruijn GJM (2019) NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol 16: 19–27. https://doi.org/10.1038/s41423-018-0024-0

130.

Hillmen P, Young NS, Schubert J et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. https://doi.org/10.1056/NEJMoa061648

131.

DeZern AE, Brodsky RA (2015) Paroxysmal nocturnal hemoglobinuria. A Complement-Mediated Hemolytic Anemia. Hematol Oncol Clin North Am 29:479–494.https://doi.org/10.1016/j.hoc.2015.01.005

132.

Tauber SC, Nau R (2008) Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 1:68–79

133.

Manda-Handzlik A, Bystrzycka W, Sieczkowska S et al (2017) Antibiotics modulate the ability of neutrophils to release neutrophil extracellular traps. Adv Exp Med Biol 944:47–52. https://doi.org/10.1007/5584_2016_59CrossRefPubMed

134.

Bystrzycka W, Manda-Handzlik A, Sieczkowska S et al (2017) Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release. Int J Mol Sci 18:2666. https://doi.org/10.3390/ijms18122666CrossRefPubMedCentral

135.

Gando S (2010) Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med

136.

Licata G, Tuttolomondo A, Di Raimondo D et al (2009) Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost. https://doi.org/10.1160/TH08-06-0375

137.

Nguyen D, Coull BM (2017) Thrombosis. In: Primer on cerebrovascular diseases, second edn

138.

Helms J, Clere-Jehl R, Bianchini E et al (2017) Thrombomodulin favors leukocyte microvesicle fibrinolytic activity, reduces NETosis and prevents septic shock-induced coagulopathy in rats. Ann Intensive Care 7:118. https://doi.org/10.1186/s13613-017-0340-zCrossRefPubMedPubMedCentral

139.

Dahlbäck B, Villoutreix BO (2005) The anticoagulant protein C pathway. FEBS Lett. https://doi.org/10.1016/j.febslet.2005.03.001

140.

Howard BM, Cohen MJ (2016) Activated protein C. In: Trauma Induced Coagulopathy pp 91–114. https://doi.org/10.1007/978-3-319-28308-1

141.

Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109:3161–3172. https://doi.org/10.1182/blood-2006-09-003004

142.

Griffin JH, Fernández JA, Gale AJ, Mosnier LO (2007) Activated protein C. J Thromb Haemost 5:73–80. https://doi.org/10.1111/j.1538-7836.2007.02491.x.

143.

Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. https://doi.org/10.1056/NEJM200103083441001

144.

Vincent JL, Bernard GR, Beale R et al (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. https://doi.org/10.1097/01.CCM.0000181729.46010.83

145.

Skene PJ, Henikoff S (2013) Histone variants in pluripotency and disease. Development

146.

Arrowsmith CH, Bountra C, Fish PV et al (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov

147.

Chen R, Kang R, Fan XG, Tang D (2014) Release and activity of histone in diseases. Cell Death Dis

148.

Iba T, Hashiguchi N, Nagaoka I et al (2015) Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp 3:1–11. https://doi.org/10.1186/s40635-015-0072-zCrossRef

149.

Wildhagen KCAAAA, De Frutos PG, Reutelingsperger CP et al (2014) Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood 123:1098–1101. https://doi.org/10.1182/blood-2013-07-514984CrossRefPubMed

150.

Sanchez J (2017) Low molecular weight heparins—a new tool to disetangle from the NETs. Pharmacol Res 123:157PubMedCrossRef

151.

Manfredi AA, Rovere-Querini P, D’Angelo A, Maugeri N (2017) Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacol Res 123:146–156. https://doi.org/10.1016/j.phrs.2016.08.008CrossRefPubMed

152.

Yang X, Wang H, Zhang M et al (2015) HMGB1: a novel protein that induced platelets active and aggregation via Toll-like receptor-4, NF-κB and cGMP dependent mechanisms. Diagn Pathol 10:134. https://doi.org/10.1186/s13000-015-0348-3

153.

Maugeri N, Franchini S, Campana L et al (2012) Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity. https://doi.org/10.3109/08916934.2012.719946

154.

Stark K, Philippi V, Stockhausen S et al (2016) Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood. https://doi.org/10.1182/blood-2016-04-710632

155.

Jong SP, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Phys Cell Physiol. https://doi.org/10.1152/ajpcell.00401.2005

156.

Andrassy M, Volz HC, Igwe JC et al (2008) High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.108.769331

157.

Huang H, Tohme S, Al-Khafaji AB et al (2015) Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology 62:600–614. https://doi.org/10.1002/hep.27841CrossRefPubMed

158.

Ma YH, Ma TT, Wang C et al (2016) High-mobility group box 1 potentiates antineutrophil cytoplasmic antibody-inducing neutrophil extracellular traps formation. Arthritis Res Ther. https://doi.org/10.1186/s13075-015-0903-z

159.

Tadie JM, Bae HB, Jiang S et al (2013) HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4. Am J Physiol Lung Cell Mol Physiol 304:L342. https://doi.org/10.1152/ajplung.00151.2012CrossRefPubMedPubMedCentral

160.

Dyer MR, Chen Q, Haldeman S et al (2018) Deep vein thrombosis in mice is regulated by platelet HMGB1 through release of neutrophil-extracellular traps and DNA. Sci Rep. https://doi.org/10.1038/s41598-018-20479-x

161.

Kang R, Zhang Q, Hou W et al (2014) Intracellular HMGB1 inhibits inflammatory nucleosome release and limits acute pancreatitis in mice. Gastroenterology 146:1097–1107.e8. https://doi.org/10.1053/j.gastro.2013.12.015CrossRefPubMed

162.

Okuma Y, Liu K, Wake H et al (2012) Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. https://doi.org/10.1002/ana.23602

163.

Liu K, Mori S, Takahashi HK et al (2007) Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. https://doi.org/10.1096/fj.07-8770com

164.

Davis AE, Lu F, Mejia P (2010) C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 104:886-93. https://doi.org/10.1160/TH10-01-0073

165.

Bouillet L, Boccon-Gibod I, Gompel A et al (2017) Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a french cohort. Eur J Dermatol https://www.ncbi.nlm.nih.gov/pubmed?term=28251901. Accessed 13 May 2020

166.

Zuraw BL, Bork K, Binkley KE et al (2012) Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 33 Suppl 1:S145-S156. https://doi.org/10.2500/aap.2012.33.3627

167.

Wygrecka M, Kosanovic D, Wujak L et al (2017) Antihistone properties of C1 esterase inhibitor protect against lung injury. Am J Respir Crit Care Med 196:186–199. https://doi.org/10.1164/rccm.201604-0712OCCrossRefPubMed

168.

Singer M, Jones AM (2010) Bench-to-bedside review: the role of C1-esterase inhibitor in sepsis and other critical illnesses. Crit Care 15:203CrossRef

169.

Liu D, Cai S, Gu X et al (2003) C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol. https://doi.org/10.4049/jimmunol.171.5.2594

170.

Lu F, Fernandes SM, Davis AE (2013) The effect of C1 inhibitor on myocardial ischemia and reperfusion injury. Cardiovasc Pathol. https://doi.org/10.1016/j.carpath.2012.05.003

171.

Caliezi C, Wuillemin WA, Zeerleder S et al (2000) C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52:91–112PubMed

172.

Lefrançais E, Looney MR (2017) Neutralizing extracellular histones in acute respiratory distress syndrome. Am J Respir Crit Care Med 196:122–124PubMedPubMedCentralCrossRef

173.

Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585. https://doi.org/10.1007/s00125-017-4342-z

174.

Campbell JM (2019) Metformin. In: Encyclopedia of biomedical gerontology

175.

Martin-Montalvo A, Mercken EM, Mitchell SJ et al (2013) Metformin improves healthspan and lifespan in mice. Nat Commun. https://doi.org/10.1038/ncomms3192

176.

Menegazzo L, Scattolini V, Cappellari R et al (2018) The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol 55:593–601. https://doi.org/10.1007/s00592-018-1129-8CrossRefPubMed

177.

Gallo A, Ceolotto G, Pinton P et al (2005) Metformin prevents glucose-induced protein kinase C-β2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes. https://doi.org/10.2337/diabetes.54.4.1123

178.

Batchuluun B, Inoguchi T, Sonoda N et al (2014) Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2013.10.025

179.

Keyaerts E, Vijgen L, Maes P et al (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. https://doi.org/10.1016/j.bbrc.2004.08.085

180.

Savarino A, Boelaert JR, Cassone A et al (2003) Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis Lancet Infect Dis 3:722–727. https://doi.org/10.1016/S1473-3099(03)00806-5

181.

Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antivir Res 177. https://doi.org/10.1016/j.antiviral.2020.104762

182.

Cortegiani A, Ingoglia G, Ippolito M et al (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. https://doi.org/10.1016/j.jcrc.2020.03.005

183.

Suarez-Almazor ME, Belseck E, Shea B et al (2000) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd000959

184.

Amin M, Pushpakumar S, Muradashvili N et al (2016) Regulation and involvement of matrix metalloproteinases in vascular diseases. Front Biosci Landmark 21:89–118CrossRef

185.

Vira H, Pradhan V, Umare V et al (2019) Role of polymorphisms in MMP-9 and TIMP-1 as biomarkers for susceptibility to systemic lupus erythematosus patients. Biomark Med 13:33–43. https://doi.org/10.2217/bmm-2018-0169CrossRefPubMed

186.

Murthy P, Singhi AD, Ross MA et al (2019) Enhanced neutrophil extracellular trap formation in acute pancreatitis contributes to disease severity and is reduced by chloroquine. Front Immunol:10. https://doi.org/10.3389/fimmu.2019.00028

187.

Boone BA, Murthy P, Miller-Ocuin J et al (2018) Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer 18. https://doi.org/10.1186/s12885-018-4584-2

188.

Boone BA, Orlichenko L, Schapiro NE et al (2015) The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther 22:326–334. https://doi.org/10.1038/cgt.2015.21CrossRefPubMedPubMedCentral

189.

Riganti C, Gazzano E, Polimeni M et al (2004) Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem. https://doi.org/10.1074/jbc.M406314200

190.

Massart C, Giusti N, Beauwens R et al (2014) Diphenyleneiodonium, an inhibitor of NOXes and DUOXes, is also an iodide-specific transporter. FEBS Open Bio. https://doi.org/10.1016/j.fob.2013.11.007

191.

Hasan RN, Schafer AI (2008) Hemin upregulates Egr-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2-Elk-1 and NF-κB. Circ Res. https://doi.org/10.1161/CIRCRESAHA.107.155143

192.

Ostafin M, Pruchniak MP, Ciepiela O et al (2016) Different procedures of diphenyleneiodonium chloride addition affect neutrophil extracellular trap formation. Anal Biochem 509:60–66. https://doi.org/10.1016/j.ab.2016.05.003CrossRefPubMed

193.

Hodgman MJ, Garrard AR (2012) A review of acetaminophen poisoning. Crit Care Clin 28:499–516. https://doi.org/10.1016/j.ccc.2012.07.006

194.

Dekhuijzen PN, van Beurden WJ (2006) The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 1:99–106. https://doi.org/10.2147/copd.2006.1.2.99

195.

Aruoma OI, Halliwell B, Hoey BM, Butler J (1989) The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. https://doi.org/10.1016/0891-5849(89)90066-X

196.

Aldini G, Altomare A, Baron G et al (2018) N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res 52:751–762. https://doi.org/10.1080/10715762.2018.1468564

197.

Zawrotniak M, Kozik A, Rapala-Kozik M (2015) View of selected mucolytic, anti-inflammatory and cardiovascular drugs change the ability of neutrophils to form extracellular traps (NETs). https://doi.org/10.18388/abp.2015_1055

198.

Craver BM, Ramanathan G, Hoang S et al (2020) N-Acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm. Blood Adv. https://doi.org/10.1182/bloodadvances.2019000967

199.

Shak S, Capon DJ, Hellmiss R et al (1990) Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 87:9188–9192. https://doi.org/10.1073/pnas.87.23.9188CrossRefPubMedPubMedCentral

200.

Sharma P, Garg N, Sharma A et al (2019) Nucleases of bacterial pathogens as virulence factors, therapeutic targets and diagnostic markers. Int J Med Microbiol 309:151354PubMedCrossRef

201.

Nishino T, Morikawa K (2002) Structure and function of nucleases in DNA repair: shape, grip and blade of the DNA scissors. Oncogene 21:9022–9032PubMedCrossRef

202.

Ain QU, Chung JY, Kim YH (2015) Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. J Control Release 205:120–127. https://doi.org/10.1016/j.jconrel.2014.12.036

203.

Macanovic M, Sinicropi D, Shak S et al (1996) The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 106:243–252. https://doi.org/10.1046/j.1365-2249.1996.d01-839.xCrossRefPubMedPubMedCentral

204.

Meng W, Paunel-Görgülü A, Flohé S et al (2012) Deoxyribonuclease is a potential counter regulator of aberrant neutrophil extracellular traps formation after major trauma. Mediat Inflamm. https://doi.org/10.1155/2012/149560

205.

Gray RD, McCullagh BN, McCray PB (2015) NETs and CF lung disease: current status and future prospects. Antibiotics 4:62–75PubMedPubMedCentralCrossRef

206.

Mohanty T, Fisher J, Bakochi A et al (2019) Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis. Nat Commun 10. https://doi.org/10.1038/s41467-019-09040-0

207.

Albadawi H, Oklu R, Raacke Malley RE et al (2016) Effect of DNase I treatment and neutrophil depletion on acute limb ischemia-reperfusion injury in mice. J Vasc Surg 64:484–493. https://doi.org/10.1016/j.jvs.2015.01.031

208.

Trejo-Becerril C, Pérez-Cardenas E, Gutiérrez-Díaz B et al (2016) Antitumor effects of systemic DNAse i and proteases in an in vivo model. Integr Cancer Ther. https://doi.org/10.1177/1534735416631102

209.

Kaplan JB, Lovetri K, Cardona ST et al (2012) Recombinant human DNase i decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo). https://doi.org/10.1038/ja.2011.113

210.

Saffarzadeh M, Juenemann C, Queisser MA et al (2012) Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One 7. https://doi.org/10.1371/journal.pone.0032366

211.

Jin T, Bokarewa M, Foster T et al (2004) Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 172:1169–1176. https://doi.org/10.4049/jimmunol.172.2.1169CrossRefPubMed

212.

Thammavongsa V, Missiakas DM, Schneewind O (2013) Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 342(80):863–866. https://doi.org/10.1126/science.1242255CrossRefPubMedPubMedCentral

213.

Ryu S, Song PI, Seo CH et al (2014) Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides. Int J Mol Sci. https://doi.org/10.3390/ijms15058753

214.

McCarthy AJ, Lindsay JA (2013) Staphylococcus aureus innate immune evasion is lineage-specific: a bioinfomatics study. Infect Genet Evol. https://doi.org/10.1016/j.meegid.2013.06.012

215.

Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S et al (2012) Probiotic mechanisms of action. Ann Nutr Metab 61:160–174. https://doi.org/10.1159/000342079

216.

Soccol CR, de Souza Vandenberghe LP, Spier MR et al (2010) The potential of probiotics: a review. Food Technol Biotechnol 48:413–434

217.

Doron S, Snydman DR (2015) Risk and safety of probiotics. Clin Infect Dis. https://doi.org/10.1093/cid/civ085

218.

Vong L, Lorentz RJ, Assa A et al (2014) Probiotic lactobacillus rhamnosus inhibits the formation of neutrophil extracellular traps. J Immunol. https://doi.org/10.4049/jimmunol.1302286

219.

Liu PT, Stenger S, Li H et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (80). https://doi.org/10.1126/science.1123933

220.

Harvey NC, Cantorna MT (2013) Vitamin D and the immune system. In: Diet, immunity and inflammation pp 244–263. https://doi.org/10.1533/9780857095749.2.244

221.

Bikle D (2009) Nonclassic actions of vitamin D. J Clin Endocrinol Metab 94:26–34. https://doi.org/10.1210/jc.2008-1454

222.

Hewison M (2012) An update on vitamin D and human immunity. Clin Endocrinol 76:315–325. https://doi.org/10.1111/j.1365-2265.2011.04261.x

223.

Fischer K (2019) Vitamin D. In: Principles of nutrigenetics and nutrigenomics: fundamentals of individualized nutrition pp 245–254. https://doi.org/10.1016/B978-0-12-804572-5.00032-X

224.

Brighton TA, Eikelboom JW, Mann K et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367:1979–1987. https://doi.org/10.1056/NEJMoa1210384CrossRefPubMed

225.

Wood AJJ, Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330:1287–1294. https://doi.org/10.1056/NEJM199405053301808CrossRef

226.

Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817. https://doi.org/10.1056/NEJMoa003199CrossRefPubMed

227.

Léon C, Ravanat C, Freund M et al (2003) Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 23:1941–1947. https://doi.org/10.1161/01.ATV.0000092127.16125.E6CrossRefPubMed

228.

Flaumenhaft R (2003) Molecular basis of platelet granule secretion. Arterioscler Thromb Vasc Biol 23:1152–1160PubMedCrossRef

229.

Weber C (2005) Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96:612–616PubMedCrossRef

230.

Carestia A, Kaufman T, Schattner M (2016) Platelets: new bricks in the building of neutrophil extracellular traps. Front Immunol 7:271PubMedPubMedCentralCrossRef

231.

Merza M, Rahman M, Zhang S et al (2014) Human thrombin-derived host defense peptides inhibit neutrophil recruitment and tissue injury in severe acute pancreatitis. Am J Physiol Liver Physiol 307:G914–G921. https://doi.org/10.1152/ajpgi.00237.2014CrossRef

232.

Jenne CN, Wong CHY, Zemp FJ et al (2013) Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 13:169–180. https://doi.org/10.1016/j.chom.2013.01.005CrossRefPubMed

233.

Schaible HG, Ebersberger A, Segond Von Banchet G (2002) Mechanisms of pain in arthritis. Ann N Y Acad Sci

234.

Attur M, Krasnokutsky S, Statnikov A et al (2015) Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers. Arthritis Rheum. https://doi.org/10.1002/art.39279

235.

Hair PS, Enos AI, Krishna NK, Cunnion KM (2018) Inhibition of immune complex complement activation and neutrophil extracellular trap formation by peptide inhibitor of complement C1. Front Immunol 9:558. https://doi.org/10.3389/fimmu.2018.00558CrossRefPubMedPubMedCentral

236.

Botto M, Kirschfink M, Macor P et al (2009) Complement in human diseases: lessons from complement deficiencies. Mol Immunol

237.

Klaska I, Nowak JZ (2007) The role of complement in physiology and pathology. Postepy Hig Med Dosw (Online) 61:167-77

238.

Weiler H, Isermann BH (2003) Thrombomodulin. J Thromb Haemost 1:1515–1524. https://doi.org/10.1046/j.1538-7836.2003.00306.x

239.

Conway EM (2012) Thrombomodulin and its role in inflammation. Semin Immunopathol 34:107–125. https://doi.org/10.1007/s00281-011-0282-8

240.

Fuentes-Prior P, Iwanaga Y, Huber R et al (2000) Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. https://doi.org/10.1038/35006683

241.

Arnold DM, Kukaswadia S, Nazi I et al (2013) A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. https://doi.org/10.1111/jth.12052

242.

Sørensen OE, Borregaard N (2016) Neutrophil extracellular traps - the dark side of neutrophils. J Clin Invest 126:1612–1620PubMedPubMedCentralCrossRef

243.

Griffin JH, Zlokovic BV, Mosnier LO (2015) Activated protein C: biased for translation. Blood 125:2898–2907. https://doi.org/10.1182/blood-2015-02-355974

244.

Healy LD, Puy C, Fernández JA et al (2017) Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. J Biol Chem 292:8616–8629. https://doi.org/10.1074/jbc.M116.768309CrossRefPubMedPubMedCentral

245.

Okajima K (2001) Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 184:258–274. https://doi.org/10.1034/j.1600-065x.2001.1840123.x

246.

Kalil AC, LaRosa SP (2012) Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(12)70157-3

247.

Acquisto NM (2014) Heparin. In: Encyclopedia of toxicology, third edn

248.

Wardrop D, Keeling D (2008) The story of the discovery of heparin and warfarin. Br J Haematol 141:757–763. https://doi.org/10.1111/j.1365-2141.2008.07119.x

249.

Tsung A, Tohme S, Billiar TR (2014) High-mobility group box-1 in sterile inflammation. J Intern Med 276:425–443. https://doi.org/10.1111/joim.12276

250.

Tang D, Kang R, Zeh HJ, Lotze MT (2011) High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 14:1315–1335. https://doi.org/10.1089/ars.2010.3356

251.

Malarkey CS, Churchill MEA (2012) The high mobility group box: the ultimate utility player of a cell. Trends Biochem Sci 37:553–562. https://doi.org/10.1016/j.tibs.2012.09.003

252.

Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342. https://doi.org/10.1038/nri1594

253.

Park JS, Svetkauskaite D, He Q et al (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. https://doi.org/10.1074/jbc.M306793200

254.

Mayansky AN, Mayansky NA (2009) Late-acting cytokine HMGBI: mediatory functions and prospects for clinical application. Immunologiya 4:232–237

255.

Lee SA, Kwak MS, Kim S, Shin JS (2014) The role of high mobility group box 1 in innate immunity. Yonsei Med J 55:1165–1176. https://doi.org/10.3349/ymj.2014.55.5.1165

256.

Matsuoka N, Itoh T, Watarai H et al (2010) High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest. https://doi.org/10.1172/JCI41360

257.

Maugeri N, Campana L, Gavina M et al (2014) Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost. https://doi.org/10.1111/jth.12710

258.

de Agostini A, Lijnen HR, Pixley RA et al (1984) Inactivation of factor XII active fragment in normal plasma. Predominant role of C1-inhibitor. J Clin Invest 73:1542–1549. https://doi.org/10.1172/JCI111360CrossRefPubMedPubMedCentral

259.

Schapira M, Scott CF, Colman RW (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69:462–468. https://doi.org/10.1172/JCI110470CrossRefPubMedPubMedCentral

260.

Stelton CR, Connors DB, Walia SS, Walia HS (2013) Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol 32:895–898. https://doi.org/10.1007/s10067-013-2226-2

261.

Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166PubMedCrossRef

262.

Jang C-H, Choi J-H, Jue D-M (2006) Chloroquine inhibits production of TNF-a, IL-1b and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45:703–710. https://doi.org/10.1093/rheumatology/kei282CrossRefPubMed

263.

Belisario MA, Maturo M, Avagnale G et al (1996) In vitro effect of avarone and avarol, a quinone/hydroquinone couple of marine origin, on platelet aggregation. Pharmacol Toxicol 79:300–304. https://doi.org/10.1111/j.1600-0773.1996.tb00013.xCrossRefPubMed

264.

Bourboulia D, Stetler-Stevenson WG (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20:161–168PubMedPubMedCentralCrossRef

265.

Lee JM, Kronbichler A, Park SJ et al (2019) Association between serum matrix metalloproteinase- (MMP-) 3 levels and systemic lupus erythematosus: a meta-analysis. Dis Markers 2019. https://doi.org/10.1155/2019/9796735

266.

Lesiak A, Narbutt J, Sysa-Jedrzejowska A et al (2010) Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19:683–688. https://doi.org/10.1177/0961203309356455CrossRefPubMed

267.

Wozniacka A, Lesiak A, Narbutt J et al (2006) Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15:268–275. https://doi.org/10.1191/0961203306lu2299oaCrossRefPubMed

268.

Qiao F, Pan P, Yan J et al (2019) Role of tumor-derived extracellular vesicles in cancer progression and their clinical applications (review). Int J Oncol 54:1525–1533. https://doi.org/10.3892/ijo.2019.4745CrossRefPubMed

269.

Leal AC, Mizurini DM, Gomes T et al (2017) Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci Rep:7. https://doi.org/10.1038/s41598-017-06893-7

270.

Prietl B, Treiber G, Pieber TR, Amrein K (2013) Vitamin D and immune function. Nutrients 5:2502–2521. https://doi.org/10.3390/nu5072502

271.

Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69:842–856.https://doi.org/10.1093/ajcn/69.5.842

272.

Handono K, Sidarta YO, Pradana BA et al (2016) Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones 46:189–198

273.

Bushra R, Aslam N (2010) An overview of clinical pharmacology of Ibuprofen. Oman Med J 25(3):155–1661. https://doi.org/10.5001/omj.2010.49CrossRefPubMedPubMedCentral

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study

Perspective: Application of the American College of Medical Genetics Variant Interpretation Criteria to Common Variable Immunodeficiency Disorders

Inflammasomes and Childhood Autoimmune Diseases: A Review of Current Knowledge

Chronic Granulomatous Disease: a Comprehensive Review